CREATIVE MEDICAL TECHNOLOGY (CELZ) Stock Price, Quote, News and Overview
NASDAQ:CELZ - Nasdaq - US22529Y4089 - Common Stock - Currency: USD
CELZ Quote, Performance and Key Statistics
NASDAQ:CELZ (6/12/2025, 8:00:00 PM)
2.2
0 (0%)
The current stock price of CELZ is 2.2 USD. In the past month the price increased by 7.84%. In the past year, price decreased by -47.12%.
CELZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.74 | 339.89B | ||
| AMGN | AMGEN INC | 14.32 | 159.86B | ||
| GILD | GILEAD SCIENCES INC | 14.48 | 139.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.78 | 56.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.73B | ||
| ARGX | ARGENX SE - ADR | 102.05 | 35.83B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.07 | 29.91B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.22B | ||
| NTRA | NATERA INC | N/A | 22.44B | ||
| BIIB | BIOGEN INC | 8.36 | 19.39B | ||
| INSM | INSMED INC | N/A | 17.65B |
Related stock screener links
About CELZ
Company Profile
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Company Info
CREATIVE MEDICAL TECHNOLOGY
211 E. Osborn Rd.
Phoenix ARIZONA US
Employees: 4
Phone: 14803992822
CREATIVE MEDICAL TECHNOLOGY / CELZ FAQ
What is the stock price of CREATIVE MEDICAL TECHNOLOGY today?
The current stock price of CELZ is 2.2 USD.
What is the ticker symbol for CREATIVE MEDICAL TECHNOLOGY stock?
The exchange symbol of CREATIVE MEDICAL TECHNOLOGY is CELZ and it is listed on the Nasdaq exchange.
On which exchange is CELZ stock listed?
CELZ stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CREATIVE MEDICAL TECHNOLOGY stock?
7 analysts have analysed CELZ and the average price target is 26.52 USD. This implies a price increase of 1105.45% is expected in the next year compared to the current price of 2.2. Check the CREATIVE MEDICAL TECHNOLOGY stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CREATIVE MEDICAL TECHNOLOGY worth?
CREATIVE MEDICAL TECHNOLOGY (CELZ) has a market capitalization of 5.70M USD. This makes CELZ a Nano Cap stock.
How many employees does CREATIVE MEDICAL TECHNOLOGY have?
CREATIVE MEDICAL TECHNOLOGY (CELZ) currently has 4 employees.
What are the support and resistance levels for CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
CREATIVE MEDICAL TECHNOLOGY (CELZ) has a support level at 2.04 and a resistance level at 2.37. Check the full technical report for a detailed analysis of CELZ support and resistance levels.
Is CREATIVE MEDICAL TECHNOLOGY (CELZ) expected to grow?
The Revenue of CREATIVE MEDICAL TECHNOLOGY (CELZ) is expected to decline by -100% in the next year. Check the estimates tab for more information on the CELZ EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CELZ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CELZ, evaluating the profitability, health, valuation and growth aspects
- CREATIVE MEDICAL TECHNOLOGY (CELZ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CREATIVE MEDICAL TECHNOLOGY (CELZ) Sales and EPS estimates to see what analysts future expectations are.
- CREATIVE MEDICAL TECHNOLOGY (CELZ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CREATIVE MEDICAL TECHNOLOGY (CELZ) Insider and Institutional Ownership to learn about the owners and their transactions.
- CREATIVE MEDICAL TECHNOLOGY (CELZ) Stock Chart to make your own analysis
- CREATIVE MEDICAL TECHNOLOGY (CELZ) Latest news and press-releases to stay up to date.
Does CREATIVE MEDICAL TECHNOLOGY (CELZ) stock pay dividends?
CELZ does not pay a dividend.
When does CREATIVE MEDICAL TECHNOLOGY (CELZ) report earnings?
CREATIVE MEDICAL TECHNOLOGY (CELZ) will report earnings on 2025-08-07.
What is the Price/Earnings (PE) ratio of CREATIVE MEDICAL TECHNOLOGY (CELZ)?
CREATIVE MEDICAL TECHNOLOGY (CELZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.81).
What is the Short Interest ratio of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
The outstanding short interest for CREATIVE MEDICAL TECHNOLOGY (CELZ) is 0.63% of its float. Check the ownership tab for more information on the CELZ short interest.
CELZ Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CELZ. When comparing the yearly performance of all stocks, CELZ is a bad performer in the overall market: 94.22% of all stocks are doing better.
CELZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CELZ. CELZ has a great financial health rating, but its profitability evaluates not so good.
CELZ Financial Highlights
Over the last trailing twelve months CELZ reported a non-GAAP Earnings per Share(EPS) of -3.81. The EPS decreased by -2.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.96% | ||
| ROE | -75.55% | ||
| Debt/Equity | 0 |
CELZ Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CELZ. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 44.19% and a revenue growth -100% for CELZ